A transactivation-deficient mouse model provides insights into Trp53 regulation and function

Nature Genetics

Volumn 26, Issue 1, 2000, Pages 37-43

  Jimenez, Gretchen S ^a,d   Nister, Monica ^b   Stommel, Jayne M ^a,c   Beeche, Michelle ^a   Barcarse, Erin A ^a   Zhang, Xiao Qun ^b   O'Gorman, Stephen ^a   Wahl, Geoffrey M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER; CANCER INHIBITION; CELL CYCLE; CELL NUCLEUS; CONTROLLED STUDY; DNA DAMAGE; FIBROBLAST; GENE FUNCTION; GENE LOCATION; GENE STRUCTURE; MOUSE; MUTANT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; APOPTOSIS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CELL CYCLE; CELL FUSION; CELL NUCLEUS; CODON; CYTOPLASM; DACTINOMYCIN; DNA DAMAGE; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENES, P53; GENOTYPE; GLUTAMINE; HUMANS; LEUCINE; MICE; MICE, NUDE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MODELS, ANIMAL; MODELS, GENETIC; MUTAGENESIS; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PHENOTYPE; PLASMIDS; PRECIPITIN TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS P21(RAS); RECOMBINATION, GENETIC; RETROVIRIDAE; SERINE; SIGNAL TRANSDUCTION; STEM CELLS; THYMUS GLAND; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRYPTOPHAN; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0033821977     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/79152     Document Type: Article

References (40)

1. Ko, L.J. & Prives, C. p53: puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
2. Giaccia, A.J. & Kastan, M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983 (1998).
3. Attardi, L.D., Lowe, S.W., Brugarolas, J. & Jacks, T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15, 3693-3701 (1996).
4. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K.H. & Oren, M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9, 2170-2183 (1995).
5. Sabbatini, P., Lin, J., Levine, A.J. & White, E. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9, 2184-2192 (1995).
6. Walker, K.K. & Levine, A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl Acad Sci. USA 93, 15335-15340 (1996).
7. Lee, S., Elenbaas, B., Levine, A. & Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81, 1013-1020 (1995).
8. Mummenbrauer, T. et al. p53 Protein exhibits 3′-to-5′ exonuclease activity. Cell 85, 1089-1099 (1996).
9. Sturzbecher, H.W., Donzelmann, B., Henning, W., Knippschild, U. & Buchhop, S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15, 1992-2002 (1996).
10. Lin, J., Chen, J., Elenbaas, B. & Levine, A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246 (1994).
11. O'Gorman, S., Dagenais, N.A., Qian, M. & Marchuk, Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Prof. Natl Acad. Sci. USA 94, 14602-14607 (1997).
12. Sah, V.P. et al. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10, 175-180 (1995).
13. Kussie, P.H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
14. Kubbutat, M.H., Jones, S.N. & Vousden, K.H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997).
15. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
16. Juven-Gershon, T. & Oren, M. Mdm2: the ups and downs. Mol. Med. 5, 71-83 (1999).
17. McLure, K.G. & Lee, P.W. How p53 binds DNA as a tetramer. EMBO J. 17, 3342-3350 (1998).
18. Zauberman, A., Barak, Y., Ragimov, N., Levy, N. & Oren, M. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J. 12, 2799-2808 (1993).
19. Kapoor, M., Hamm, R., Yan, W., Taya, Y. & Lozano, G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19, 358-364 (2000).
20. Bottger, A. et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269, 744-756 (1997).
21. Ljungman, M., Zhang, F., Chen, F., Rainbow, A.J. & McKay, B.C. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18, 583-592 (1999).
22. Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T. & Levine, A.J. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17, 554-564 (1998).
23. Freedman, D.A. & Levine, A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18, 7288-7293 (1998).
24. Stommel, J.M. et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660-1672 (1999).
25. de Stanchina, E. et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12, 2434-2442 (1998).
26. Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433 (1998).
27. Khan, S.K., Moritsugu, J. & Wahl, G.M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption and ribonucleotide depletion. Proc. Natl Acad. Sci. USA 97, 3266-3271 (2000).
28. Sherr, C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991 (1998).
29. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
30. Linke, S.P., Clarkin, K.C., Di Leonardo, A., Tsou, A. & Wahl, G.M. A reversible p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10, 934-947 (1996).
31. Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
32. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
33. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
34. Wahl, G.M., Linke, S.P., Paulson, T.G. & Huang, L.C. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 29, 183-219 (1997).
35. Ford, J.M. & Hanawalt, P.C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc. Natl Acad. Sci. USA 92, 8876-8880 (1995).
36. Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49 (2000).
37. Wang, X.W. et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10, 1219-1232 (1996).
38. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T. & Mulligan, R.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163 (1991).
39. Jimenez, G.S. et al. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature 400, 81-83 (1999).
40. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992)